Circ Heart Fail. 2015 Jan;8(1):98-108. doi: 10.1161/CIRCHEARTFAILURE.114.001180. Epub 2014 Nov 24.
Sexual dimorphism of Doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling.
Moulin M1, Piquereau J2, Mateo P2, Fortin D2, Rucker-Martin C2, Gressette M2, Lefebvre F2, Gresikova M2, Solgadi A2, Veksler V2, Garnier A2, Ventura-Clapier R2.
Circulation. 2015 Jan 15. pii: CIRCULATIONAHA.114.008750. [Epub ahead of print]
Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension.
Ranchoux B1, Antigny F1, Rucker-Martin C1, Hautefort A1, Péchoux C2, Bogaard HJ3, Dorfmüller P4, Remy S5, Lecerf F1, Planté S6, Chat S2, Fadel E7, Houssaini A8, Anegon I5, Adnot S8, Simonneau G1, Humbert M1, Cohen-Kaminsky S1, Perros F9.
Chest. 2015 Feb 1;147(2):529-37. doi: 10.1378/chest.14-0862.
New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication.
Guignabert C, Tu L, Girerd B, Ricard N, Huertas A, Montani D, Humbert M.
Am J Pathol. 2015 Feb;185(2):356-71. doi: 10.1016/j.ajpath.2014.10.021. Epub 2014 Dec 11.
Chemotherapy-induced pulmonary hypertension: role of alkylating agents.
Ranchoux B1, Günther S2, Quarck R3, Chaumais MC4, Dorfmüller P5, Antigny F1, Dumas SJ1, Raymond N5, Lau E2, Savale L2, Jaïs X2, Sitbon O2, Simonneau G2, Stenmark K6, Cohen-Kaminsky S1, Humbert M2, Montani D2, Perros F7.
J Am Coll Cardiol. 2015 Feb 24;65(7):668-80. doi: 10.1016/j.jacc.2014.11.050.
Nebivolol for Improving Endothelial Dysfunction, Pulmonary Vascular Remodeling, and Right Heart Function in Pulmonary Hypertension.
Perros F, Ranchoux B, Izikki M, Bentebbal S, Happé C, Antigny F, Jourdon P, Dorfmüller P, Lecerf F, Fadel E, Simonneau G, Humbert M, Bogaard HJ, Eddahibi S.
Eur Respir J. 2015 Apr;45(4):1066-80. doi: 10.1183/09031936.00193014. Epub 2015 Mar 5.
Leptin signalling system as a target for pulmonary arterial hypertension therapy.
Huertas A, Tu L, Thuillet R, Le Hiress M, Phan C, Ricard N, Nadaud S, Fadel E, Humbert M, Guignabert C.